Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 20/20 | 0.52 |
| ▸ | AKT1 | P31749 | 20/20 | 0.52 |
| ▸ | PRKCB | P05771 | 2/20 | 0.52 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1662712 | 0.99 | RPS6KB1 (0.52) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| Tert-Butyl Formate SCHEMBL27962329 | 0.88 | RPS6KB1 (0.48) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| Hydrochloric Acid SCHEMBL16457169 | 0.86 | RPS6KB1 (0.43) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| Hydrochloric Acid SCHEMBL16457612 | 0.83 | RPS6KB1 (0.45) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| SCHEMBL27962398 | 0.83 | RPS6KB1 (0.55) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| Succinic Acid SCHEMBL27962324 | 0.82 | RPS6KB1 (0.44) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| Hydrochloric Acid SCHEMBL16457487 | 0.82 | RPS6KB1 (0.37) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| SCHEMBL16457175 | 0.82 | RPS6KB1 (0.40) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| SCHEMBL12798736 | 0.81 | RPS6KB1 (0.51) | RPS6KB1AKT1PRKCBRPS6KA1 | |
| SCHEMBL14782369 | 0.81 | RPS6KB1 (0.64) | RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299362-B1 | IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3299362-A1 | IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9315517-B2 | Imidazol-piperidinyl derivatives as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| EP-2920154-A1 | NOVEL IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| CN-102574852-B | AKT inhibitors | LILLY CO ELI | 2014-06-25 | — | — | CN | disclosed |
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | RPS6KB1 41/4885AKT1 4/4885PRKCB 176/4885 |
| US-20150239902-A1 | Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity | MAP4K2, MAP4K3, MAP3K4 | RPS6KB1 318/4885AKT1 197/4885PRKCB 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.